Quince Therapeutics (NASDAQ:QNCX) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Quince Therapeutics (NASDAQ:QNCX) in a research report sent to investors on Wednesday morning,Benzinga reports. D. Boral Capital currently has a $4.00 price objective on the stock.

Several other equities analysts have also issued reports on the stock. Wall Street Zen lowered shares of Quince Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Oppenheimer started coverage on shares of Quince Therapeutics in a report on Monday, March 24th. They set an “outperform” rating and a $10.00 price objective on the stock. One analyst has rated the stock with a sell rating, five have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $8.00.

Quince Therapeutics Stock Performance

Shares of NASDAQ:QNCX opened at $1.17 on Wednesday. The firm has a market cap of $53.20 million, a PE ratio of -0.94 and a beta of 0.80. The firm’s 50 day simple moving average is $1.06 and its 200-day simple moving average is $1.45. Quince Therapeutics has a one year low of $0.51 and a one year high of $2.45. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53.

Quince Therapeutics (NASDAQ:QNCX) last issued its earnings results on Tuesday, May 13th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). As a group, equities analysts predict that Quince Therapeutics will post -1.21 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Anfield Capital Management LLC purchased a new position in Quince Therapeutics in the fourth quarter valued at $50,000. Virtu Financial LLC purchased a new position in Quince Therapeutics in the fourth quarter valued at $55,000. Two Sigma Investments LP purchased a new position in Quince Therapeutics in the fourth quarter valued at $57,000. Intellectus Partners LLC purchased a new position in Quince Therapeutics in the first quarter valued at $71,000. Finally, Northern Trust Corp increased its holdings in Quince Therapeutics by 48.5% in the fourth quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock valued at $94,000 after buying an additional 16,501 shares in the last quarter. 30.75% of the stock is currently owned by institutional investors and hedge funds.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.